IBRX:NASDAQ, ImmunityBio, Inc.
IBRX stock overview
ImmunityBio, Inc. (IBRX:NASDAQ) closed at $5.98 on November 16, 2026,
down 0.66% on the day.
The stock trades 51.9% below its 52-week high of $12.43
and 206.7% above its 52-week low of $1.95.
Over the past year, it gained 184.8%.
ImmunityBio, Inc. is part of the Health Care sector.
Key figures
- Price
- $5.98
- Day change
- -0.66%
- Volume
- 12,799,375
- Average volume
- 12,643,115
- Market cap
- 6B+
- 52-week range
- $1.95 – $12.43
- 50-day average
- $8.59
- 200-day average
- $7.97
Price action over the past year
In 252 trading sessions since November 14, 2025, IBRX closed higher on 123 days (49%).
Its best day was February 18, 2026 (+41.86%) and its worst was March 24, 2026 (-21.12%).
The stock moved 10% or more in a single session 22 times.
It opened at least 5% above the previous day's high 5 times.
Recent signals
IBRX news
-
Nov 16, 2026:
SLS, IBRX And IOVA Join Merck And Lilly On BlackRock's Q3 Buy List — A Vanguard Unit Adds All Of Them Too
-
Nov 16, 2026:
SLS, IBRX And IOVA Join Merck And Lilly On BlackRocks Q3 Buy List A Vanguard Unit Adds All Of Them Too
-
Nov 13, 2026:
IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio's London Conferences Next Week
-
Nov 13, 2026:
IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 All Eyes On ImmunityBios London Conferences Next Week
-
Nov 13, 2026:
IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth' NantWorks Reveals — Cancer Tech, AI Chips And Satellites
-
Nov 13, 2026:
IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of Stealth NantWorks Reveals Cancer Tech, AI Chips And Satellites
-
Nov 13, 2026:
ImmunityBio (IBRX) is Declining For 4 Days Now. What's Triggering the Selloff?
-
Nov 12, 2026:
IBRX Stock Eyes Worst Week In Nearly 2 Years — But Anktiva's Sepsis Trial Potential Fuels Retail Bets On Big Pharma Appeal
About ImmunityBio, Inc.
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.
Similar stocks
Find more stocks like IBRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.